cd3/cd19 negative allogeneic hematopoietic stem cells
Immunodeficiency With Predominant T-cell Defect, Unspecified
Paul SzabolcsCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Immunodeficiency With Predominant T-cell Defect, Unspecified cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Equine Atg | Phase 1/2 | CCC |
Fludarabine | Phase 1/2 | CCC |
Busulphan | Phase 1/2 | CCC |
Cyclophosphamide The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | D | |
Docetaxel The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | D |
Same molecule, other indications
cd3/cd19 negative allogeneic hematopoietic stem cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →